Form 8-K Cyclacel Pharmaceuticals For: May 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cyclacel Pharma (CYCC) Posts Wider Q1 Loss
May 12, 2021 4:25 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($1.48), $0.99 worse than the analyst estimate of ($0.49).
During the quarter, we have made significant progress in bringing our two oral targeted development candidates into mid-stage clinical development. Following recent FDA authorization of our IND for oral... More
